Migraine and patent foramen ovaleApproximately 10-15% of all Europeans suffer from migraines. Recent research suggests, among other things, a link between migraines and a common heart defect, a patent foramen ovale (PFO, "oval hole"). A PFO is a small opening between the upper chambers of the heart, which occurs in about 25% of the population. Blood flowing through this opening bypasses the filtration system of the lungs.

Studies have shown that people who suffer from severe migraines are more likely to have a patent foramen ovale (PFO). Therefore, it is suspected that migraine attacks are triggered by small blood clots that reach the brain along with unfiltered blood passing through the PFO. In certain cases, these blood clots can disrupt brain metabolism and cause migraine attacks.

The PRIMA study on patent foramen ovale and migraine

The current study on migraine is examining patients in whom this possible connection between their headaches and the PFO is to be clarified.

The Kiel Pain Clinic is one of the international testing centers where neurologists and cardiologists are investigating this connection.

What is the PRIMA study?

This clinical study helps determine whether a common heart defect, patent foramen ovale (PFO), contributes to migraine attacks.

The PRIMA study is a randomized trial. This means that participants have a 50:50 chance of receiving PFO closure and the corresponding treatment, or of receiving treatment according to the current standard without PFO closure.

The minimally invasive procedure takes about an hour and is performed by specialized cardiologists.

How is the PRIMA study conducted?

Participants are randomly assigned to one of two groups. One group receives the PFO closure and is treated according to current standards. The second group does not receive the closure but is treated according to current standards.

Study participants will receive free care as part of the study. Specialized physicians will monitor both patient groups throughout the study period. The results will be recorded and compared for both groups. The study has been reported to the relevant authorities.

Who can participate?

To participate in the PRIMA study, the following criteria must be met:

  • Ages between 18 and 65, whereby the onset of migraine attacks must have occurred before the age of 50
  • Diagnosis of migraine with aura
  • Unsuccessful treatment with at least two generally accepted preventive medications

Even if you meet the above criteria, your further medical history and other factors will be taken into account to determine whether you are eligible for the study.

Participation in the study is free of charge.

How do I get included in the PRIMA study?

If you would like more information about the PRIMA study, please contact our registration office:

  • Tel.: 0431-20099400.

A series of questions will be answered to determine if you meet the basic criteria. If so, an appointment for a personal examination will be scheduled. Before participating in the study, participants will receive an informed consent form, which they must read and which contains further information about the therapy within the study and what to expect. The study design will be explained in detail, and participants will have the opportunity to ask questions.

The initial tests for inclusion in the study include:

  • the recording of the medical history,
  • a headache diary kept over 3 months,
  • completing the questionnaire on quality of life,
  • the Beck Depression Inventory (BDI),
  • completing the questionnaire to assess your functional impairment due to migraine (MIDAS questionnaire),
  • clinical neurological examinations,
  • Routine blood tests, ECG and TCD (transcranial Doppler ultrasound) or TTE (transthoracic echo) for right-to-left shunt.

What happens after I am enrolled in the study?

Patients are asked to keep a headache diary and receive neurological monitoring for one year. Patients undergoing PFO closure are also monitored by a cardiologist during this time and examined annually thereafter.

You can find more information in the information flyer .

Source: http://primatrial.com/